US Patent

US11304904 — Manufacturing of bupivacaine multivesicular liposomes

Method of Use · Assigned to Pacira Pharmaceuticals Inc · Expires 2041-01-22 · 15y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a commercial manufacturing process for making bupivacaine multivesicular liposomes using dual tangential flow filtration modules.

USPTO Abstract

Embodiments of the present application relate to commercial manufacturing processes for making bupivacaine multivesicular liposomes (MVLs) using independently operating dual tangential flow filtration modules.

Drugs covered by this patent

Bupivacaine Hydrochloride And Epinephrine (BUPIVACAINE) · Innocoll

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3346`	—	Bupivacaine Hydrochloride And Epinephrine
`U-3346`	—	Bupivacaine Hydrochloride And Epinephrine

Patent Metadata

Patent number: US11304904
Jurisdiction: US
Classification: Method of Use
Expires: 2041-01-22
Drug substance claim: No
Drug product claim: Yes
Assignee: Pacira Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.